Fukuoka M, Masuda N, Negoro S, Matsui K, Yana T, Kudoh S, Kusunoki Y, Takada M, Kawahara M, Ogawara M, Kodama N, Kubota K, Furuse K
Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan.
Br J Cancer. 1997;75(2):306-9. doi: 10.1038/bjc.1997.50.
Sixty-three patients with extensive-stage small-cell lung cancer were randomized to receive either cyclophosphamide, vincristine, doxorubicin and etoposide (CODE) alone or CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF). rhG-CSF administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs (P = 0.03) with a significant improvement in survival (P = 0.004).
63例广泛期小细胞肺癌患者被随机分为两组，一组单独接受环磷酰胺、长春新碱、阿霉素和依托泊苷（CODE方案）治疗，另一组接受CODE方案加重组人粒细胞集落刺激因子（rhG-CSF）治疗。支持CODE化疗的rhG-CSF给药使所有药物的平均总接受剂量强度增加（P = 0.03），生存率显著提高（P = 0.004）。
